Multi-institutional analysis of solitary extramedullary plasmacytoma of the head and neck treated with curative radiotherapy

Ryohei Sasaki, Koichi Yasuda, Eisuke Abe, Nobue Uchida, Mitsuhiko Kawashima, Takashi Uno, Masayuki Fujiwara, Yoshiyuki Shioyama, Yoshikazu Kagami, Yuta Shibamoto, Kensei Nakata, Yoshie Takada, Tetsuya Kawabe, Kazuyuki Uehara, Kenichi Nibu, Syogo Yamada

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Purpose: The purpose of this study was to elucidate the efficacy and optimal method of radiotherapy in the management of solitary extramedullary plasmacytoma occurring in the head and neck regions (EMPHN). Methods and Materials: Sixty-seven patients (43 male and 24 female) diagnosed with EMPHN between 1983 and 2008 at 23 Japanese institutions were reviewed. The median patient age was 64 years (range, 12-83). The median dose administered was 50 Gy (range, 30-64 Gy). Survival data were calculated by the Kaplan-Meier method. Results: The median follow-up duration was 63 months. Major tumor sites were nasal or paranasal cavities in 36 (54%) patients, oropharynx or nasopharynx in 16 (23%) patients, orbita in 6 (9%) patients, and larynx in 3 (5%) patients. The 5- and 10-year local control rates were 95% and 87%, whereas the 5- and 10-year disease-free survival rates were 56% and 54%, respectively. There were 5 (7.5%), 12 (18%), and 8 (12%) patients who experienced local failure, distant metastasis, and progression to multiple myeloma, respectively. In total, 18 patients died, including 10 (15%) patients who died due to complications from EMPHN. The 5- and 10-year overall survival (OS) rates were 73% and 56%, respectively. Radiotherapy combined with surgery was identified as the lone significant prognostic factor for OS (p = 0.04), whereas age, gender, radiation dose, tumor size, and chemotherapy were not predictive. No patient experienced any severe acute morbidity. Conclusions: Radiotherapy was quite effective and safe for patients with EMPHN. Radiotherapy combined with surgery produced a better outcome according to survival rates. These findings require confirmation by further studies with larger numbers of patients with EMPHN.

Original languageEnglish
Pages (from-to)626-634
Number of pages9
JournalInternational Journal of Radiation Oncology Biology Physics
Volume82
Issue number2
DOIs
Publication statusPublished - Feb 1 2012

Fingerprint

Plasmacytoma
radiation therapy
Neck
Radiotherapy
Head
Survival Rate
surgery
tumors
larynx
dosage
Oropharynx
Survival
Nasopharynx
metastasis
chemotherapy
Larynx
Multiple Myeloma
Nose
progressions
Disease-Free Survival

All Science Journal Classification (ASJC) codes

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Multi-institutional analysis of solitary extramedullary plasmacytoma of the head and neck treated with curative radiotherapy. / Sasaki, Ryohei; Yasuda, Koichi; Abe, Eisuke; Uchida, Nobue; Kawashima, Mitsuhiko; Uno, Takashi; Fujiwara, Masayuki; Shioyama, Yoshiyuki; Kagami, Yoshikazu; Shibamoto, Yuta; Nakata, Kensei; Takada, Yoshie; Kawabe, Tetsuya; Uehara, Kazuyuki; Nibu, Kenichi; Yamada, Syogo.

In: International Journal of Radiation Oncology Biology Physics, Vol. 82, No. 2, 01.02.2012, p. 626-634.

Research output: Contribution to journalArticle

Sasaki, R, Yasuda, K, Abe, E, Uchida, N, Kawashima, M, Uno, T, Fujiwara, M, Shioyama, Y, Kagami, Y, Shibamoto, Y, Nakata, K, Takada, Y, Kawabe, T, Uehara, K, Nibu, K & Yamada, S 2012, 'Multi-institutional analysis of solitary extramedullary plasmacytoma of the head and neck treated with curative radiotherapy', International Journal of Radiation Oncology Biology Physics, vol. 82, no. 2, pp. 626-634. https://doi.org/10.1016/j.ijrobp.2010.11.037
Sasaki, Ryohei ; Yasuda, Koichi ; Abe, Eisuke ; Uchida, Nobue ; Kawashima, Mitsuhiko ; Uno, Takashi ; Fujiwara, Masayuki ; Shioyama, Yoshiyuki ; Kagami, Yoshikazu ; Shibamoto, Yuta ; Nakata, Kensei ; Takada, Yoshie ; Kawabe, Tetsuya ; Uehara, Kazuyuki ; Nibu, Kenichi ; Yamada, Syogo. / Multi-institutional analysis of solitary extramedullary plasmacytoma of the head and neck treated with curative radiotherapy. In: International Journal of Radiation Oncology Biology Physics. 2012 ; Vol. 82, No. 2. pp. 626-634.
@article{0cd171a6d30544c098eeeebc2efb7196,
title = "Multi-institutional analysis of solitary extramedullary plasmacytoma of the head and neck treated with curative radiotherapy",
abstract = "Purpose: The purpose of this study was to elucidate the efficacy and optimal method of radiotherapy in the management of solitary extramedullary plasmacytoma occurring in the head and neck regions (EMPHN). Methods and Materials: Sixty-seven patients (43 male and 24 female) diagnosed with EMPHN between 1983 and 2008 at 23 Japanese institutions were reviewed. The median patient age was 64 years (range, 12-83). The median dose administered was 50 Gy (range, 30-64 Gy). Survival data were calculated by the Kaplan-Meier method. Results: The median follow-up duration was 63 months. Major tumor sites were nasal or paranasal cavities in 36 (54{\%}) patients, oropharynx or nasopharynx in 16 (23{\%}) patients, orbita in 6 (9{\%}) patients, and larynx in 3 (5{\%}) patients. The 5- and 10-year local control rates were 95{\%} and 87{\%}, whereas the 5- and 10-year disease-free survival rates were 56{\%} and 54{\%}, respectively. There were 5 (7.5{\%}), 12 (18{\%}), and 8 (12{\%}) patients who experienced local failure, distant metastasis, and progression to multiple myeloma, respectively. In total, 18 patients died, including 10 (15{\%}) patients who died due to complications from EMPHN. The 5- and 10-year overall survival (OS) rates were 73{\%} and 56{\%}, respectively. Radiotherapy combined with surgery was identified as the lone significant prognostic factor for OS (p = 0.04), whereas age, gender, radiation dose, tumor size, and chemotherapy were not predictive. No patient experienced any severe acute morbidity. Conclusions: Radiotherapy was quite effective and safe for patients with EMPHN. Radiotherapy combined with surgery produced a better outcome according to survival rates. These findings require confirmation by further studies with larger numbers of patients with EMPHN.",
author = "Ryohei Sasaki and Koichi Yasuda and Eisuke Abe and Nobue Uchida and Mitsuhiko Kawashima and Takashi Uno and Masayuki Fujiwara and Yoshiyuki Shioyama and Yoshikazu Kagami and Yuta Shibamoto and Kensei Nakata and Yoshie Takada and Tetsuya Kawabe and Kazuyuki Uehara and Kenichi Nibu and Syogo Yamada",
year = "2012",
month = "2",
day = "1",
doi = "10.1016/j.ijrobp.2010.11.037",
language = "English",
volume = "82",
pages = "626--634",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Multi-institutional analysis of solitary extramedullary plasmacytoma of the head and neck treated with curative radiotherapy

AU - Sasaki, Ryohei

AU - Yasuda, Koichi

AU - Abe, Eisuke

AU - Uchida, Nobue

AU - Kawashima, Mitsuhiko

AU - Uno, Takashi

AU - Fujiwara, Masayuki

AU - Shioyama, Yoshiyuki

AU - Kagami, Yoshikazu

AU - Shibamoto, Yuta

AU - Nakata, Kensei

AU - Takada, Yoshie

AU - Kawabe, Tetsuya

AU - Uehara, Kazuyuki

AU - Nibu, Kenichi

AU - Yamada, Syogo

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Purpose: The purpose of this study was to elucidate the efficacy and optimal method of radiotherapy in the management of solitary extramedullary plasmacytoma occurring in the head and neck regions (EMPHN). Methods and Materials: Sixty-seven patients (43 male and 24 female) diagnosed with EMPHN between 1983 and 2008 at 23 Japanese institutions were reviewed. The median patient age was 64 years (range, 12-83). The median dose administered was 50 Gy (range, 30-64 Gy). Survival data were calculated by the Kaplan-Meier method. Results: The median follow-up duration was 63 months. Major tumor sites were nasal or paranasal cavities in 36 (54%) patients, oropharynx or nasopharynx in 16 (23%) patients, orbita in 6 (9%) patients, and larynx in 3 (5%) patients. The 5- and 10-year local control rates were 95% and 87%, whereas the 5- and 10-year disease-free survival rates were 56% and 54%, respectively. There were 5 (7.5%), 12 (18%), and 8 (12%) patients who experienced local failure, distant metastasis, and progression to multiple myeloma, respectively. In total, 18 patients died, including 10 (15%) patients who died due to complications from EMPHN. The 5- and 10-year overall survival (OS) rates were 73% and 56%, respectively. Radiotherapy combined with surgery was identified as the lone significant prognostic factor for OS (p = 0.04), whereas age, gender, radiation dose, tumor size, and chemotherapy were not predictive. No patient experienced any severe acute morbidity. Conclusions: Radiotherapy was quite effective and safe for patients with EMPHN. Radiotherapy combined with surgery produced a better outcome according to survival rates. These findings require confirmation by further studies with larger numbers of patients with EMPHN.

AB - Purpose: The purpose of this study was to elucidate the efficacy and optimal method of radiotherapy in the management of solitary extramedullary plasmacytoma occurring in the head and neck regions (EMPHN). Methods and Materials: Sixty-seven patients (43 male and 24 female) diagnosed with EMPHN between 1983 and 2008 at 23 Japanese institutions were reviewed. The median patient age was 64 years (range, 12-83). The median dose administered was 50 Gy (range, 30-64 Gy). Survival data were calculated by the Kaplan-Meier method. Results: The median follow-up duration was 63 months. Major tumor sites were nasal or paranasal cavities in 36 (54%) patients, oropharynx or nasopharynx in 16 (23%) patients, orbita in 6 (9%) patients, and larynx in 3 (5%) patients. The 5- and 10-year local control rates were 95% and 87%, whereas the 5- and 10-year disease-free survival rates were 56% and 54%, respectively. There were 5 (7.5%), 12 (18%), and 8 (12%) patients who experienced local failure, distant metastasis, and progression to multiple myeloma, respectively. In total, 18 patients died, including 10 (15%) patients who died due to complications from EMPHN. The 5- and 10-year overall survival (OS) rates were 73% and 56%, respectively. Radiotherapy combined with surgery was identified as the lone significant prognostic factor for OS (p = 0.04), whereas age, gender, radiation dose, tumor size, and chemotherapy were not predictive. No patient experienced any severe acute morbidity. Conclusions: Radiotherapy was quite effective and safe for patients with EMPHN. Radiotherapy combined with surgery produced a better outcome according to survival rates. These findings require confirmation by further studies with larger numbers of patients with EMPHN.

UR - http://www.scopus.com/inward/record.url?scp=84855822887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855822887&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2010.11.037

DO - 10.1016/j.ijrobp.2010.11.037

M3 - Article

C2 - 21277117

AN - SCOPUS:84855822887

VL - 82

SP - 626

EP - 634

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 2

ER -